Osimertinib as adjuvant therapy in patients with resected EGFRm stage IB-IIIA NSCLC: updated results from ADAURA

被引：0

作者：

Grohe, C. ^{[1
]}

Tsuboi, M. ^{[2
]}

Wu, Y. ^{[3
,4
]}

John, T. ^{[5
]}

Majem, M. ^{[6
]}

Wang, J. ^{[7
]}

Kato, T. ^{[8
]}

Goldman, J. ^{[9
]}

Kim, S. ^{[10
]}

Yu, C. ^{[11
,12
]}

Vu, H. ^{[13
]}

Mukhametshina, G. ^{[14
]}

Akewanlop, C. ^{[15
]}

de Marinis, F. ^{[16
]}

Shepherd, F. ^{[17
]}

Urban, D. ^{[18
,19
]}

Stachowiak, M. ^{[20
]}

Balanos, A. ^{[20
]}

Huang, X. ^{[20
]}

Herbst, R. ^{[21
,22
]}

Kern, J. ^{[15
,23
]}

机构：

[1] Evangel Lungenklin Berlin Buch, Berlin, Germany

[2] Natl Canc Ctr Hosp East, Kashiwa, Japan

[3] Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China

[4] Guangdong Acad Med Sci, Guangzhou, Peoples R China

[5] Austin Hlth, Heidelberg, Australia

[6] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[7] Chinese Acad Med Sci, Beijing, Peoples R China

[8] Kanagawa Canc Ctr, Asahi Ward, Asahi, Japan

[9] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA

[10] Asan Med Ctr, Seoul, South Korea

[11] Natl Taiwan Univ Hosp, Taipei, Taiwan

[12] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[13] Cho Ray Hosp, Ho Chi Minh City, Vietnam

[14] Republican Clin Oncol Ctr, Kazan City, Russia

[15] Siriraj Hosp, Bangkok, Thailand

[16] IRCCS, European Inst Oncol Ieo, San Giovanni Rotondo, Italy

[17] Princess Margaret Canc Ctr, Univ Hlth Network, Toronto, ON, Canada

[18] Sheba Med Ctr, Tel Hashomer, Israel

[19] Sackler Fac Med, Tel Hashomer, Israel

[20] Astrazeneca, Cambridge, England

[21] Yale Sch Med, New Haven, CT USA

[22] Yale Canc Ctr, New Haven, CT USA

[23] Kwm Missio Clin, Wurzburg, Germany

来源：

PNEUMOLOGIE | 2023年 / 77卷

关键词：

D O I：

10.1055/s-0043-1760904

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

FV 96

引用

页码：S17 / S17

页数：1

共 50 条

[11] Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC
Majem, M.
Goldman, J.
John, T.
Grohe, C.
Laktionov, K. K.
Kim, S.
Kato, T.
Vu, H. V.
Lu, S.
Lee, K. Y.
Akewanlop, C.
Yu, C.
De Marinis, F.
Bonanno, L.
Domine, M.
Shepherd, F.
Zeng, L.
Kulkarni, D.
Medic, N.
Tsuboi, M.
Herbst, R.
Wu, Y.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S112 - S113
[12] Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC)
John, Tom
Grohe, Christian
Goldman, Jonathan W.
Kato, Terufumi
Laktionov, Konstantin K.
Bonanno, Laura
Tiseo, Marcello
Majem, Margarita
Domine, Manuel, Sr.
Ahn, Myung-Ju
Perol, Maurice
Hartmaier, Ryan
Robichaux, Jacqulyne
Bhetariya, Preetida
Markovets, Aleksandra
Rukazenkov, Yuri
Muldoon, Caitlin
Herbst, Roy S.
Tsuboi, Masahiro
Wu, Yi-Long
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[13] Patient Reports from ADAURA: HRQol Data on Osimertinib as adjuvant Therapy in Patients with resected EGFR-mutated (EGFRm) NSCLC
Engel-Riedel, W.
Majem, M.
Goldman, J. W.
Grohe, C.
John, T.
Laktionov, K.
Kim, S.
Kato, T.
Vu, H. V.
Lu, S.
Lee, K.
Akewanlop, C.
Yu, C. J.
de Marinis, F.
Bonanno, L.
Domine, M.
Shepherd, F. A.
Zeng, L.
Kulkarni, D.
Medic, N.
Tsuboi, M.
Herbst, R. S.
Wu, Y. L.
Wohlleber, M.
PNEUMOLOGIE, 2021, 75 : S21 - S21
[14] IMpower010: results from Asian patients in a phase 3 study of adjuvant atezolizumab in resected stage IB-IIIA NSCLC
Kenmotsu, Hirotsugu
Zhou, Caicun
Altorki, Nasser
Felip, Enriqueta
Vallieres, Eric
Sugawara, Shunichi
Sakai, Hiroshi
Saito, Haruhiro
Tao, Min
Kawaguchi, Koji
Liu, Yunpeng
Yu, Chong-Jen
Wu, Qiong
Lin, Huang
Wu, Fan
Bennett, Elizabeth
Mcnally, Virginia
Gitlitz, Barbara
Wakelee, Heather
ANNALS OF ONCOLOGY, 2022, 33 : S464 - S464
[15] Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR plus NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
Zhang, Shannon S.
Ou, Sai-Hong Ignatius
LUNG CANCER-TARGETS AND THERAPY, 2022, 13 : 23 - 31
[16] Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence
Tsuboi, M.
Wu, Y-L.
He, J.
John, T.
Grohe, C.
Majem, M.
Goldman, J. W.
Laktionov, K.
Kim, S-W.
Kato, T.
Vu, H. V.
Akewanlop, C.
Yu, C-J.
de Marinis, F.
Domine, M.
Shepherd, F. A.
Yan, C.
Atasoy, A.
Herbst, R.
ANNALS OF ONCOLOGY, 2020, 31 : S1177 - S1177
[17] Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial (vol 41, pg 3877, 2023)
不详
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (22) : 3877 - 3877
[18] Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence
Tsuboi, M.
Wu, Y-L.
He, J.
John, T.
Grohe, C.
Majem, M.
Goldman, J. W.
Laktionov, K.
Kim, S-W.
Kato, T.
Vu, H. V.
Akewanlop, C.
Yu, C-J.
de Marinis, F.
Domine, M.
Shepherd, F. A.
Yan, C.
Atasoy, A.
Herbst, R.
ANNALS OF ONCOLOGY, 2020, 31 : S1378 - S1378
[19] EGFR mutation (EGFRm) prevalence and mortality in patients with stage IB-IIIA NSCLC: A cohort study in Denmark
Jakobsen, E.
Taylor, A.
Ehrenstein, V.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S730 - S731
[20] Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
Brazel, Danielle
Nagasaka, Misako
LUNG CANCER-TARGETS AND THERAPY, 2022, 13 : 47 - 52

← 1 2 3 4 5 →